Zentalis CEO Sells $21,239 in Shares as Company Narrows Development Focus
Zentalis Pharmaceuticals CEO Julia Marie Eastland sold 8,755 shares of common stock via automatic transactions on February 6 and 9, 2026, to cover tax withholding tied to vested restricted stock units. The trades totaled $21,239 at prices between $2.3929 and $2.4297. The company recently halted active development of azenosertib for uterine serous c…